BMS engages with Immatics

Wednesday 15 December 2021
Country

Germany

Bristol Myers Squibb Co has launched its second preclinical collaboration with Immatics NV in order to explore the potential of an antibody-like bispecific molecule as a treatment for solid tumours. The newest agreement, announced on 14 December, gives BMS exclusive rights to an engineered bispecific molecule consisting of a receptor that binds to a cancer target and a region that recruits T cells to the tumour site to become activated. The upfront payment is $150 million.